Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based biopharmaceutical firm Chimerix has revealed its decision to stop further participation in all current and future clinical trials of its Ebola drug, brincidofovir.
Subscribe to our email newsletter
The announcement also includes the study in Liberia sponsored by investigators at the University of Oxford and the supportive Phase II trial of brincidofovir for Ebola Virus Disease (EVD), Study 205.
The trials have been stopped after observing significant decrease in the number of new cases of confirmed EVD in Liberia over the last several weeks.
The trial of brincidofovir in Liberia is led by the University of Oxford and International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) with operational support from Médecins Sans Frontières (MSF).
The company said that the decision to cease further trials does not impact its continued focus on advancing brincidofovir in pivotal studies of cytomegalovirus (CMV) prevention in recipients of allogeneic hematopoietic transplant and to treat adenovirus infection in immunocompromised patients.
Chimerix president and CEO Michelle Berrey said: "We were honored to be able to work with the researchers at University of Oxford and ISARIC together with MSF to initiate the first clinical trial of an investigational agent during an outbreak.
"The progress in controlling the Ebola outbreak in Liberia is to be commended.
"Chimerix will continue to push forward with our development of brincidofovir for the prevention and treatment of serious viral infections in transplant recipients and other immunocompromised patients."